Abiomed, Inc. provided earnings guidance for the fiscal year 2022. For the period, the company expects global revenue to be in the range of $1,030 million to $1,050 million, representing 22% to 24% growth compared to fiscal year 2021, an increase from the original guidance of $990 million to $1,030 million, or 17% to 22% growth compared to fiscal year 2021.